-
TGen identifies compound that could improve drug development against brain cancer
A study led by scientists at the Translational Genomics Research Institute (TGen) has identified "a potent inhibitory compound" in the elusive hunt for an improved treatment against glioblastoma, the most common and deadly type of adult brain cancer.Aurintricarboxylic Acid (ATA) is a chemical compound that in laboratory tests was shown to block the chemical cascade that otherwise…